Last reviewed · How we verify

NCT06664385

Effect of a Concurrent Physical Exercise Program in Hemodialysis Patients

Completed NA Last updated 31 October 2024
What this trial tests

NA trial testing concurrent physical exercise in Chronic Renal Insufficiency in 40 participants. Completed in 9 August 2024.

Timeline
1 July 2024
Primary endpoint
9 August 2024
9 August 2024

Quick facts

Lead sponsorPedro Julian Flores Moreno
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment40
Start date1 July 2024
Primary completion9 August 2024
Estimated completion9 August 2024
Sites1 location across Mexico

Drugs / interventions tested

Conditions studied

Sponsor

Pedro Julian Flores Moreno

Who can join

19 and older, any sex, with Chronic Renal Insufficiency or Hemodialysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Concurrent physical exercise is the method of combining strength and endurance that can be worked with in one session or in an exercise program. Therefore, the researchers seek to implement it in patients suffering from chronic renal failure with hemodialysis therapy and see if concurrent physical exercise improves quality of life levels and at the same time see the response of physical fitness, body composition and biochemistry.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Renal Insufficiency

Currently open trials in the same condition.

Other Pedro Julian Flores Moreno trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06664385.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing